Latest Herceptin Stories
Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.
Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very aggressive disease.
Patients with HER2-positive breast cancer may have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin.
Adding AfinitorÂ® to HerceptinÂ®, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies.
SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S.
ASCO Abstract #10504. Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin.
- Large; stout; burly.